Intrexon

The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
Yahoo/Benzinga
AHA
The Medicines Company
Intrexon
Alnylam
Pieris
Roche
Flag link:
4 US pharma execs make Forbes 400 list
4 US pharma execs make Forbes 400 list
BioPharma Dive
Patrick Soon-Shiong
NantWorks
Phillip Frost
OPKO Health
Randal Kirk
Intrexon
Robert Duggan
Pharmacyclics
Flag link:
7 Companies in the Fight to Defeat the Zika Virus
7 Companies in the Fight to Defeat the Zika Virus
24/7 Wall St
Zika virus
R&D
Gilead Sciences
Inovio
Intrexon
NewLink Genetics
Quest Diagnostics
Sanofi
Flag link:
The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution
The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution
Motley Fool
Zika virus
Invovio
GSK
NewLink Genetics
Sanofi
Merck
Cerus
Intrexon
Flag link:
Is ZIOPHARM Poised For Acquisition?
Is ZIOPHARM Poised For Acquisition?
Seeking Alpha
Ziopharm
M&A
Intrexon
Flag link:
3 Biotech Stocks That Could Be Buyout Targetst
3 Biotech Stocks That Could Be Buyout Targetst
Motley Fool
Intrexon
Ziopharm
Bluebird Bio
Biomarin
Flag link:
Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy
Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy
Yahoo
Intrexon
Merck Serono
CAR-T
chimeric antigen receptor T-cell immunotherapies
Flag link:
This Billionaire CEO Just Made Another Biotech Acquisition -- and Hardly Anyone Noticed
This Billionaire CEO Just Made Another Biotech Acquisition -- and Hardly Anyone Noticed
Motley Fool
Intrexon
CAR-T
Zogenix
ActoGeniX
Flag link:
Booming biotechs bank $2.7B in follow-on cash
Booming biotechs bank $2.7B in follow-on cash
Fierce Biotech
biotech
Prosensa
Biomarin
Zafgen
Alnylam
Auspex
Puma Biotechnology
Arena Pharmaceuticals
Radius Health
Intrexon
Flag link:
The 10 Most Heavily Shorted Bio-Pharma Stocks
The 10 Most Heavily Shorted Bio-Pharma Stocks
TheStreet.com
Spectrum Pharmaceuticals
Dendreon
Achillion
Ziopharm
Intrexon
Arena Pharmaceuticals
Idenix
Synta Pharmaceuticals
Sarepta Therapeutics
Myriad Genetics
Flag link:
The Best- And Worst-Performing Biotech Stocks,Jan. 3 to Jan. 10
The Best- And Worst-Performing Biotech Stocks,Jan. 3 to Jan. 10
Forbes
Neurocrine
Intercept Pharma
Epizyme
Sangamo BioSciences
OncoMed
Zogenix
Macrogenics
Intrexon
Pharmacyclics
Galena Biopharma
Flag link:
Intrexon to Acquire Medistem to Generate Multipotent Cells
Intrexon to Acquire Medistem to Generate Multipotent Cells
Yahoo
Intrexon
MediStem
M&A
Flag link:
Ziopharm: Finally A Winner In The War On Cancer?
Ziopharm: Finally A Winner In The War On Cancer?
Seeking Alpha
Ziopharm
cancer
AbbVie
Amgen
Celgene
Celldex Therapeutics
Gilead Sciences
Immunogen
JNJ
ImmunoCellular Therapeutics
Pharmacyclics
Intrexon
Seattle Genetics
Flag link:
This Biotech Trifecta Could Revolutionize Cancer
This Biotech Trifecta Could Revolutionize Cancer
Motley Fool
Intrexon
Ziopharm
Amgen
Osiris Therapeutics
Flag link:
Fresh burst of biotech IPO pitches launches a busy Q4 season
Fresh burst of biotech IPO pitches launches a busy Q4 season
Fierce Biotech
IPOs
Foundation Medicine
Ophthotech
Intrexon
Onconova
Agios
OncoMed
Flag link:
3 Red Flags for This Biotech IPO
3 Red Flags for This Biotech IPO
Motley Fool
Intrexon
IPOs
Flag link:
Sun Pharma and Intrexon Form Joint Venture to Develop New Class of Therapeutics for Ocular Diseases - Angel Broking
Sun Pharma and Intrexon Form Joint Venture to Develop New Class of Therapeutics for Ocular Diseases - Angel Broking
Equity Bulls
Sun Pharma
Intrexon
wet age-related macular degeneration
age-related macular degeneration
macular
edema
uveitis
diabetic retinopathy
Flag link:
A Time to Test Biotechs' Strength
A Time to Test Biotechs' Strength
The Street
Bluebird Bio
Epizyme
Intrexon
NanoString Technologies
LipoScience
Aratana
Heat Biologics
ONYX Pharmaceuticals
Amgen
Flag link:
Is This Biotech Stock Worth Buying After a Massive Post-IPO Surge?
Is This Biotech Stock Worth Buying After a Massive Post-IPO Surge?
Motley Fool
IPOs
Intrexon
Eli Lilly
synthetic DNA
Flag link:
Biotech company Intrexon shares surge 38 pct in debut
Biotech company Intrexon shares surge 38 pct in debut
Reuters
Intrexon
IPOs
Flag link:

Pages